After a 100% gain yesterday, analysts have been upgrading the shares of $GPCR high by the dozen. In the medium term, I also see a 3-digit price trend. But of course it depends very much on the phase 3 trial results. If they disappoint, the share price will not just fall by 20-30%.
Clear Street has left the rating for Structure Therapeutics ADR (NASDAQ: GPCR) to 'buy'. The price target is $99.00 after $61.00 previously.
Prior to this rating 14 analyst(s) rated Structure Therapeutics ADR as 'Buy' and 0 as 'Hold'. There were 0 Sell recommendations.
Analyst consensus estimates and price targets for Structure Therapeutics ADR can be found at hier. For more news on Structure Therapeutics ADR please visit hier.
The Structure Therapeutics ADR share price ended the official trading session at a closing price of $69.98. The stock's performance was up 106.43% in the last month and up 101.70% in the last 12 months.
BMO Capital has set the rating for Structure Therapeutics ADR (NASDAQ: GPCR) to 'outperform'. The price target is $130.00 after $100.00 previously.